135 related articles for article (PubMed ID: 37145121)
1. Improvement in Palivizumab Administration Prior to Discharge for Hospitalized Infants with Hemodynamically Significant Congenital Heart Disease: A Quality Improvement Initiative.
Jones AL; Campbell MJ; Abernathy B; Neubert S; Hager A; Collier H; Ramsey EZ; Simon A; Schachtner S; Natarajan S
Pediatr Cardiol; 2023 May; ():. PubMed ID: 37145121
[TBL] [Abstract][Full Text] [Related]
2. A systematic review of compliance with palivizumab administration for RSV immunoprophylaxis.
Frogel MP; Stewart DL; Hoopes M; Fernandes AW; Mahadevia PJ
J Manag Care Pharm; 2010; 16(1):46-58. PubMed ID: 20131495
[TBL] [Abstract][Full Text] [Related]
3. Improving Palivizumab Administration to High-Risk Infants with Heart Disease via a Communication-Based Quality Improvement Initiative.
Leone DM; Rodriguez A; Cowenhoven K; O'Connell M; Grossman M; Ferdman D
Pediatr Cardiol; 2024 Feb; ():. PubMed ID: 38300318
[TBL] [Abstract][Full Text] [Related]
4. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
Romero JR
Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452
[TBL] [Abstract][Full Text] [Related]
5. Administration of the first dose of palivizumab immunoprophylaxis against respiratory syncytial virus in infants before hospital discharge: what is the evidence for its benefit?
Geskey JM; Ceneviva GD; Brummel GL; Graff GR; Javier MC
Clin Ther; 2004 Dec; 26(12):2130-7. PubMed ID: 15823776
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of palivizumab immunoprophylaxis in infants with respiratory syncytial virus disease in Colombia.
Piñeros JG; De la Hoz-Valle J; Galvis C; Celis A; Ovalle O; Sandoval CC; Orrego J; Vides S; Rojas I; Bustamante H; Gallón C; Mesa JA
J Infect Dev Ctries; 2021 Nov; 15(11):1708-1713. PubMed ID: 34898500
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of a novel web-based prior approval application for palivizumab prophylaxis of respiratory syncytial virus in a state Medicaid program.
Lundeen K; Pfeiffenberger T; Jacobson Vann J; O'Brien T; Sampson C; Wegner S
J Manag Care Pharm; 2013 Mar; 19(2):115-24. PubMed ID: 23461427
[TBL] [Abstract][Full Text] [Related]
8. Description of the outcomes of prior authorization of palivizumab for prevention of respiratory syncytial virus infection in a managed care organization.
Buckley BC; Roylance D; Mitchell MP; Patel SM; Cannon HE; Dunn JD
J Manag Care Pharm; 2010; 16(1):15-22. PubMed ID: 20044843
[TBL] [Abstract][Full Text] [Related]
9. Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses.
Wang D; Bayliss S; Meads C
Health Technol Assess; 2011 Jan; 15(5):iii-iv, 1-124. PubMed ID: 21281564
[TBL] [Abstract][Full Text] [Related]
10. Palivizumab prophylaxis against respiratory syncytial virus infection in patients younger than 2 years of age with congenital heart disease.
Mohammed MHA; Agouba R; Obaidy IE; Alhabshan F; Abu-Sulaiman R
Ann Saudi Med; 2021; 41(1):31-35. PubMed ID: 33550912
[TBL] [Abstract][Full Text] [Related]
11. Outcomes related to respiratory syncytial virus with an abbreviated palivizumab regimen in children with congenital heart disease: a descriptive analysis.
Claydon J; Popescu CR; Shaiba L; Christopherson C; Human D; Taylor R; Solimano A; Lavoie PM
CMAJ Open; 2019; 7(1):E88-E93. PubMed ID: 30782771
[TBL] [Abstract][Full Text] [Related]
12. Risk factors for hospitalisation due to respiratory syncytial virus infection in children receiving prophylactic palivizumab.
Chida-Nagai A; Sato H; Sato I; Shiraishi M; Sasaki D; Izumi G; Yamazawa H; Cho K; Manabe A; Takeda A
Eur J Pediatr; 2022 Feb; 181(2):539-547. PubMed ID: 34417646
[TBL] [Abstract][Full Text] [Related]
13. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections.
American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn
Pediatrics; 2003 Dec; 112(6 Pt 1):1442-6. PubMed ID: 14654627
[TBL] [Abstract][Full Text] [Related]
14. Implementation of American Academy of Pediatrics guidelines for palivizumab prophylaxis in a pediatric hospital.
Zembles TN; Gaertner KM; Gutzeit MF; Willoughby RE
Am J Health Syst Pharm; 2016 Mar; 73(6):405-8. PubMed ID: 26953285
[TBL] [Abstract][Full Text] [Related]
15. Respiratory syncytial virus morbidity and outpatient palivizumab dosing in South Carolina, 2004-2009.
Chadha AD; Bao W; Holloway J; Mann J; Rye AK; Brown DE
South Med J; 2012 Aug; 105(8):399-404. PubMed ID: 22864095
[TBL] [Abstract][Full Text] [Related]
16. Medical utilization associated with palivizumab compliance in a commercial and managed medicaid health plan.
Diehl JL; Daw JR; Coley KC; Rayburg R
J Manag Care Pharm; 2010; 16(1):23-31. PubMed ID: 20044844
[TBL] [Abstract][Full Text] [Related]
17. Infant respiratory syncytial virus prophylaxis and nasopharyngeal microbiota until 6 years of life: a subanalysis of the MAKI randomised controlled trial.
Man WH; Scheltema NM; Clerc M; van Houten MA; Nibbelke EE; Achten NB; Arp K; Sanders EAM; Bont LJ; Bogaert D
Lancet Respir Med; 2020 Oct; 8(10):1022-1031. PubMed ID: 32203712
[TBL] [Abstract][Full Text] [Related]
18. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections.
Meissner HC; Long SS;
Pediatrics; 2003 Dec; 112(6 Pt 1):1447-52. PubMed ID: 14654628
[TBL] [Abstract][Full Text] [Related]
19. Respiratory syncytial virus immunoprophylaxis in high-risk infants with heart disease.
Alexander PM; Eastaugh L; Royle J; Daley AJ; Shekerdemian LS; Penny DJ
J Paediatr Child Health; 2012 May; 48(5):395-401. PubMed ID: 22720323
[TBL] [Abstract][Full Text] [Related]
20. Initial Palivizumab Dose Administration in Outpatient Clinic After Hospital Discharge.
Stockton W; Chen Y; Jun A; Lee T; Chilvers Murphy M; Magedman G
Pediatr Infect Dis J; 2018 Nov; 37(11):1124-1129. PubMed ID: 29570593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
